With the growing availability of full genome sequencing, it is foreseeable that laboratories could identify an organism's repetitive sequences in silico to predictably and combinatorialy direct large-scale remodeling to test strain characteristics for a myriad of basic science and engineering applications.
Cheaper short read techniques therefore seem poised to dominate the sequencing market for the foreseeable future, especially given that human genome re-sequencing, the main economic driver for innovation in genome sequencing technologies, is focused on clinical personal genomics where short reads appear largely sufficient for reference assembly and SNP detection.
The foreseeable rise of nanopore sequencers and other 'third-generation' sequencers able to process single molecules of DNA may make bedside sequencing a reality.
It is not expected that Gymnosperm genomes will be sequenced in the foreseeable future, therefore we undertook a preliminary comparative analysis of protein families using the 14,471 spruce transcripts, to assess whether insights may be gained into the relative size of protein families in Gymnosperms and Angiosperms.
Even assuming a significant increase in pharmacogenetics research and decreases in the costs associated with genome sequencing, for the foreseeable future these efforts will not significantly improve our ability to predict, prevent, or diagnose diabetes or illuminate definitive pathways for selecting drug therapies for specific individuals.
Fragmented genomes should therefore be the expectation from modern genome sequencing projects, at least for the foreseeable future, given the current economic reality and the market dominance of short-read sequencing platforms.
In combination with the increasing knowledge in gene sequences this will allow in the foreseeable future widespread use in the pig industry either for agricultural or biomedical purposes.
With rapid progress in next generation sequencing technology, additional papaya whole genome sequencing may be carried out in the foreseeable future.
For the foreseeable future, however, each individual whose genome is sequenced will have vast numbers of variants of uncertain clinical significance.
In the foreseeable future, along with the development of advanced sequencing technologies and development of relevant analysis technologies, more novel and specific miRNAs will be identified from more re-sequenced or de novel sequenced species.
It is foreseeable that the burgeoning capacity for whole genome sequencing will soon provide a cost effective alternative to the current subtyping methods after a reconciliation has been made between the true nature of subtypes, the diversity revealed by classical methods and the micro- and macro-diversity readily identified by next-generation sequencing technologies.
